Physician profile
Bo Jiang
NPI 1205199536
$2,596.09
in general payments reported to CMS, 2019-2025
18 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $489 · 2023: $448 · 2024: $686 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $458.71 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $318.81 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $314.82 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.02 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $266.96 | 2023-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $179.06 | 2024-2025 | Lifevest |
| Pfizer INC. | $155.71 | 2024-2025 | |
| Novo Nordisk INC | $125.45 | 2022-2025 | Ozempic, Wegovy |
| Bridgebio Pharma, INC. | $75.18 | 2025 | Attruby |
| Amgen INC. | $61.49 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $60.47 | 2023-2024 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $52.23 | 2023 | Inpefa |
| Boston Scientific Corporation | $51.88 | 2023 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $43.54 | 2025 | |
| Amarin Pharma, INC. | $42.25 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $41.68 | 2024-2025 | Impella |
| Lilly USA, LLC | $23.20 | 2025 | Zepbound, Mounjaro |
| Atricure, INC. | $17.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bo Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.